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IntroDuCtIon
Patients with recurrent gynaecological malignancies 
frequently have symptomatic localised pelvic disease and 
high morbidity and mortality.1–3 If uncontrolled, symptoms 
(e.g. pain, vaginal bleeding and/or discharge, bladder and/or 
bowel symptoms, fistulae, lymphoedema4) are progressive, 
and adversely impact quality of life, particularly in those 
previously treated with external beam radiotherapy (EBRT) 
or brachytherapy.5 Treatment options are limited by the site 
and extent of recurrence, and the nature of previous treat-
ment. Radical radiotherapy, usually administered for recur-
rence following surgery, carries a risk of treatment-related 
toxicities, and often cannot be used after previous radio-
therapy.6 In isolated relapse, pelvic exenteration may poten-
tially be curative, but carries high (40–80%) morbidity, with 
a 20–40% 5-year survival.7,8 Used palliatively, radiotherapy 
and surgery may achieve symptomatic control, but induce 
acute bowel and bladder problems, while palliative chemo-
therapy is <20% effective at symptomatic relief within a 
previously irradiated field.9
High intensity focused ultrasound (HIFU) has been used 
for many years to treat benign gynaecological disease.10 
The thermally ablative mechanism of action is well under-
stood,11 and as HIFU does not use ionising radiation, it 
can be delivered to a previously irradiated field without 
risking additional radiation toxicity. Therefore, HIFU 
offers a potential alternative treatment in patients with 
recurrent gynaecological tumours, particularly as recur-
rence often occurs at a single site.12 However, evidence 
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objective: To assess the feasibility of targeting recurrent 
gynaecological tumours with MR guided high intensity 
focused ultrasound (MRgHIFU).
Methods: 20 patients with recurrent gynaecolog-
ical tumours were prospectively scanned on a Philips/
Profound 3 T Achieva MR/ Sonalleve HIFU system. Gross 
tumour volume (GTV) and planning target volume (PTV) 
were delineated on T2W and diffusion-weighted imaging 
(DWI). Achievable treatment volumes that (i) assumed 
bowel and/or urogenital tract preparation could be used 
to reduce risk of damage to organs-at-risk (TVoptimal), or 
(ii) assumed no preparations were possible (TVno-prep) 
were compared with PTV on virtual treatment plans. 
Patients were considered treatable if TVoptimal ≥ 50 % PTV.
results: 11/20 patients (55%) were treatable if prepara-
tion strategies were used: nine had central pelvic recur-
rences, two had tumours in metastatic locations. Treatable 
volume ranged from 3.4 to 90.3 ml, representing 70 ± 
17 % of PTVs. Without preparation, 6/20 (30%) patients 
were treatable (four central recurrences, two metastatic 
lesions). Limiting factors were disease beyond reach 
of the HIFU transducer, and bone obstructing tumour 
access. DWI assisted tumour outlining, but differences 
from T2W imaging in GTV size (16.9 ± 23.0%) and PTV 
location (3.8 ± 2.8 mm in phase-encode direction) limited 
its use for treatment planning.
Conclusions: Despite variation in size and location 
within the pelvis, ≥ 50 % of tumour volumes were 
considered targetable in 55 % patients while avoiding 
adjacent critical structures. A prospective treatment 
study will assess safety and symptom relief in a second 
patient cohort.
advances in knowledge: Target size, location and 
access make MRgHIFU a viable treatment modality 
for treating symptomatic recurrent gynaecological 
tumours within the pelvis.
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for efficacy of HIFU treatment of these tumours is extremely 
limited, comprising only two case-reports in two females with 
recurrent cervical tumours.13,14 In both cases, patients gained 
significant short-term improvements in pain and/or bleeding 
without adverse events, but long-term follow up was unavailable. 
Whilst these case reports are encouraging, and there is extensive 
evidence for HIFU treatment of uterine fibroids, the anatomical 
location of recurrent tumours is variable, and pelvic anatomy 
may be distorted by prior treatments. Consequently, the feasi-
bility of treating these lesions with a conventional extracorporeal 
HIFU system needs to be established. The purpose of this pilot 
study, therefore, was to assess the feasibility of targeting recurrent 
gynaecological tumours with MRgHIFU, prior to undertaking a 
treatment study. We set an ablation target of ≥50% of the lesion 
volume as a criterion for treatability.
MetHoDS
Study design
This was the feasibility arm of a prospective single-centre study 
investigating MRgHIFU for treatment of recurrent gynaeco-
logical malignancies (NCT02714621).15 Patients were posi-
tioned on a Sonalleve HIFU clinical system (Profound Medical 
Corp, Ontario, Canada), and scanned within the bore of a 
3T Achieva MR (Philips Healthcare, Best, The Netherlands). 
Images enabled virtual treatment plans to be constructed using 
Sonalleve treatment planning software. An arbitrary threshold 
of targeting ≥50% of a target lesion volume without damage to 
surrounding organs at risk (OARs) in ≥20% of the patients was 
set as the criterion for success to proceed to the treatment arm 
of NCT02714621.
Study Population
Over a 20-month period from June 2016 to February 2018, 
20 adult females with a proven diagnosis of locally recur-
rent gynaecological malignancy were recruited. Eligibility 
criteria for the study are provided in Table 1. Medical history, 
symptoms and any potential risk factors for anaesthesia were 
documented. Each patient was given a study-specific patient 
information sheet, before providing written, informed consent 
to participate.
Patient preparation for MRI
Patients were encouraged to drink water, and refrain from 
micturition prior to scanning, if a partly full bladder was 
thought likely to be helpful for targeting their region of 
disease. This was not pursued if the patient had concerns about 
incontinence or discomfort; instead review of the medical 
notes determined whether intervention (e.g. bladder filling 
by urinary catheter) would have been possible. No patients 
underwent preparation to vagina or bowel; instead we deter-
mined whether the region close to the target disease was likely 
to be amenable to clinically acceptable preparation strategies 
(e.g. aspiration of air, or filling with ultrasound gel).
Patient positioning and MR image acquisition
Patients were placed in a potential treatment position that 
minimised the distance between the target lesion and the 
centre of the acoustic window built into the treatment couch. 
Images were acquired with the standard Sonalleve HIFU 
window and pelvis coils. T2- and T1-weighted (T2W, T1W) 
sequences were acquired axially through the whole pelvis, 
and used to plan high-resolution 3D T2W imaging. This 
provided orthogonal image reconstructions relative to any 
planned position and angle of the transducer at the target. As 
tumour margins can be difficult to distinguish on T1W or T2W 
imaging on a background of post-surgical or radiotherapy-in-
duced tissue changes, diffusion-weighted imaging (DWI) was 
also acquired, because it provides better tumour-to-normal-
tissue contrast.16 Summary sequence parameters are provided 
in Table 2. If disease could potentially have been targeted from 
different approaches, patients underwent repeat scanning of 
the T2W imaging only in the additional treatment positions.
Measurement of gross tumour volume (GTV)
The maximum dimensions of the tumour, and its minimum 
and maximum depths from the skin were measured on 2D 
T2W imaging. GTV was calculated by manually drawing a 
region of interest (ROI) conformal to the tumour on every 
slice demonstrating it, using in-house software (Adept, The 
Institute of Cancer Research ), and summing all ROI areas 
multiplied by the slice thickness and slice gap.
Defining the planning target volume (PTV)
An ellipsoidal PTV (the only option in the available software) 
that closely encompassed the GTV (Figure 1) was defined using 
the Sonalleve treatment planning software on orthogonal multi 
planar reformats of the 3D T2W imaging, with reference to all 
available imaging. Its volume was provided by the treatment 
Table 1.Eligibility criteria for the study. Patients’ suitability for other treatments was not a consideration in this planning study 
assessing treatment feasibility
Inclusion criteria Exclusion criteria
Adult patients (≥18 years) with confirmed recurrent pelvic 
gynaecological malignancy
MRI contra indicated (e.g. by incompatible metal implants, claustrophobia or 
BMI precludes accommodation in the MRI scanner)
Intended target visible on non-contrast MRI Pregnancy
Intended target potentially within transducer range (1–10 cm beneath 
the skin)
Patient lacking capacity to consent for study
Patient willing to undergo study-specific MRI, not necessary for clinical 
care
  
Patients willing to provide details of prior medical and treatment history   
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planning software. In 16/20 patients, a single PTV was used to 
encompass the GTV. In the remaining four, better conformity 
to eccentrically shaped tumour regions was obtained by using 
two partially overlapping PTVs, whose non-overlapped sum 
represented the final PTV.
Assessing feasibility of treatment
Appropriately sized HIFU treatment cells (4, 8, 12, 14, 16 mm 
diameter; 0.1, 0.8, 2.5, 3.8, 5.6 ml volume)17 were prescribed 
manually, to cover the entire PTV. This was first done without 
considering acoustic obstacles in the beam path or OARs, but 
by simply ensuring that cells were within focal range of the 
transducer (Figure  2). These cells were then safety-checked 
to determine if they could be delivered without obstruction 
or risk, in particular whether: (i) bone was in the beam path 
(denoted by the beam overlay shown in Figure 2), (ii) MR-vis-
ible nerves were within the cell safety margin (Figure  2), or 
(iii) there was high risk of damage to the bowel or urogenital 
tract. This third assessment was made under the assumption 
that preparation could be used to minimise the risk of damage 
if these organs were located in, or close to the beam path, but 
not if they were within the cell safety margin. Total volume 
of these safety-checked cells (TVoptimal), the number and size 
of HIFU treatment cells, and estimated treatment time was 
recorded. A second treatment plan (TVno-prep) derived from 
TVoptimal, assumed that no interventional preparations were 
possible.
Comparing T2W imaging and DWI for defining GTV 
and PTV
To estimate any difference in GTV, if measured on DWI, rather 
than T2W imaging, GTVs were also outlined on DWI (DWI-
GTV), done without reference to the T2W images, and using 
both the b = 700 s/mm2 images and apparent diffusion coeffi-
cient (ADC) maps.
To estimate any difference in PTV volume and location if defined 
against different imaging techniques, PTVs were also defined 
separately on T2W imaging (T2-PTV) and DWI (DWI-PTV), 
and their volumes compared. The central co-ordinates (AP, LR 
and FH) of each PTV were read using a pixel information tool, 
and summarised as the mean value of each of the three co-ordi-
nates. Discrepancies between PTV positions were calculated as 
the magnitude difference values between each set of mean AP, 
LR and FH co-ordinates.
Statistical analysis
Statistical analysis was performed using GraphPad Prism soft-
ware (Version 7, San Diego, CA). D'Agostino & Pearson tests 
for normality were used to determine whether parametric or 
non-parametric tests should be used. p-values < 0.05 were 
considered significant.
Log-transformation of GTVs, PTVs and TVs was required to 
normalise these data, and allow the use of parametric tests. GTVs 
Table 2.T2W and diffusion-weighted imaging (DWI) sequence 
parameters. DWI sequences were voxel matched, slice 
matched to the 2D T2W imaging, and corresponded with 
every third slice of the higher resolution 3D T2W imaging
Parameter
2D TSE 
T2W
3D TSE 
T2W EPI-DWI
TR (ms) 3620 1500 9000
TE (ms) 90 165 65
FA (o) 90 90 90
Fat suppression - - SPIR & SSGR
EPI/TSE factor 16 67 69
SENSE factor 1.5 (RL) 1.5 (RL), 2.0 
(FH)
1.6 (RL)
b values (s/mm2) - - 0, 100, 700
rBW (Hz/pix) -  26.3
Shim Auto Volume Pencil beam 
volume
Voxel size (mm3) 1.0 × 1.0×4.5 1.5 × 1.5×1.5 3.5 × 3.5×4.5
FOV (mm) 280 × 
300×180
250 × 
250×200
300 × 327×185
  NSA 1 1 3
Number slices 40 133 41
Slice orientation transverse transverse transverse
Scan duration 
min:sec
02:32 02:13 4:48
Figure 1.The planning target volume (PTV) (pink ellipse) 
closely encompassed the gross tumour volume (GTV) (green 
outline), shown here on a single slice of the 2D T2W imag-
ing. The co-ordinates (AP, LR and FH) of the PTV centre (pink 
cross) were read using a pixel information tool on each of 3 
orthogonal imaging planes reconstructed from the 3D T2W 
imaging. Available Sonalleve treatment planning software did 
not allow the slice-by slice GTV outlines to be displayed within 
PTVs.
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and PTVs were compared using paired samples t-tests. The 
difference between PTV and the non-safety-checked treatment 
volume represented the proportion of disease beyond range of 
the transducer. TVoptimal and TVno-prep were each expressed as 
percentages of PTV. Patients were considered treatable if TVop-
timal was ≥50% PTV. Differences in GTV, PTV and the 2 varieties 
of TV (optimal and no-prep) between treatable and non-treat-
able patients were compared using unpaired t-tests. Volumes of 
DWI-GTVs and DWI-PTVs were compared with those outlined 
on T2W imaging using paired samples t-tests.
reSultS
Patients
Primary tumour types, locations of recurrence, and details of 
prior treatment are summarised in Table 3. All patients tolerated 
the required imaging position; in 16 this was supine oblique, one 
was prone oblique, and one was prone. In the remaining two, 
more than one position was used. No patient had contraindica-
tions to gadolinium administration, but one had potential risk 
factors for anaesthesia. One patient with disease in an inguinal 
node who had undergone a prior wide local excision had scar 
tissue in the HIFU beam path, which would have increased the 
risk of skin burn if she had gone on to have treatment.
GTV and PTV
Mean ± SD maximum tumour dimensions on T2W imaging 
were: 43.5 ± 22.4 mm (AP), 44.2 ± 22.2 mm (LR) and 45.0 ± 23.0 
mm (FH). Minimum depth of tumours from the skin was 72.3 
± 21.5 mm; maximum depth was 115.9 ± 27.7 mm. GTV varied 
across the cohort (mean ± SD: 64.2 ± 82.3 ml, range: 1.1–308.2 
ml). PTV was consequently also highly variable (mean ± SD: 
83.1 ± 104 ml, range: 1.4–357.8 ml), but was always larger than 
GTV (difference: 23.8±13.7%).
Feasibility of treatment
11/20 patients (55%) were considered treatable if preparation 
strategies were used: 9 of these had central recurrences and two 
had tumours in metastatic locations (inguinal nodes and Morri-
son’s pouch). The potential treatment volume in these patients 
was 21.9 ± 25.1 ml (range: 3.4–90.3 ml), which represented 
70±17% of PTVs. Estimated treatment time was 41.4 ± 29.2 
min (not allowing for patient positioning or imaging). Of nine 
patients not considered treatable with preparation, six also had 
central recurrences, whilst the remaining three had lesions at the 
pelvic sidewall. Examples of accessible and non-accessible central 
recurrences are shown in Figure 3. Potential treatment volumes 
in the nine non-treatable patients were larger (41.2 ± 46.0 ml, 
range 0–122 ml) than in the 11 treatable patients, but represented 
a smaller proportion of PTVs (difference: 23.4±16.8%). This was 
because both GTV and PTV were significantly smaller in the 
11 treatable patients (GTV: 27.2 ± 36.5 ml, range 1.1–128.5 ml; 
PTV: 34.2 ± 44.5 ml, range 1.4–160.3 ml), compared to the nine 
who were not treatable (GTV: 109.4 ± 101.1 ml, range 11.2–308.2 
ml; PTV: 143.2 ± 125.7 ml, range 12.4–357.8 ml, GTV p = 0.006, 
PTV p = 0.005).
Without preparation, 6/20 patients (30%) were still considered 
treatable: four with central recurrences and two with metastatic 
lesions. The potential treatable volume in these patients was 
33.1 ± 30.2 ml (range: 3.4–90.3 ml), representing 78±20% of 
PTVs.
Figure 2.Sonalleve treatment planning tools are shown overlaid on (a) an image of the QA phantom (for clarity), and (b) a patient’s 
T2W image. Treatment cells (green ellipses) are positioned within the planning target volume (PTV) (pink ellipse). The transducer 
beam overlay is indicated by the white y-shaped graphics, with the region at greatest risk of heating (cell safety margin) indicated 
by the yellow rectangle. The available target area (ATA) indicates the region within range of the transducer. Each cell was safety 
checked to determine whether bone or heat sensitive non-target regions lay within the transducer beam overlay, or within the cell 
safety margin.
5 of 9 birpublications.org/bjr Br J Radiol;92:20181037
BJRFull paper: Feasibility of MRgHIFU for treating recurrent gynaecological tumours
Table 3.Patient demographics, prior treatment history, and proposed treatment for recurrent disease. Note that some patients 
underwent more than one surgical procedure prior to the present recurrence. Only two patients who had radiotherapy for recur-
rence had also received radiotherapy to the primary tumour
Patient characteristics
Age (years)
Mean ± SD 61.4 ± 11.3
Median (range) 61.5 (44–83)
Primary Tumour Site: n (%)
Cervix 6 (30)
Ovary 5 (25)
Endometrium 5 (25)
Vulva 2 (10)
Primary peritoneal 1 (5)
Bartholin’s Gland 1 (5)
Location of recurrence: n (%)
Vagina or vault 9 (45)
Pelvic sidewall 4 (20)
Adnexa 2 (10)
Uterus 2 (10)
Inguinal region 1 (5)
Perineal region 1 (5)
Morrison’s Pouch 1 (5)
Interval primary diagnosis to present recurrence (years)
Median (range) 3.3 (0.8–28.9)
first recurrence / second recurrence / fourth recurrence n = 15/ n = 4/ n = 1
Prior surgery to primary tumour: n (%)
Any surgery 18 (90)
Hysterectomy 13 (65)
Local excision 7 (35)
Bilateral Salpingo-oopherectomy 10 (50)
Lymph node dissection 6 (30)
Exenteration 1 (5)
Prior therapy for gynae malignancy: n (%)
EBRT and brachytherapy to primary tumour 4 (20)
EBRT or brachytherapy to primary tumour 4 (20)
Radiotherapy to prior/present recurrence 8 (40)
Chemotherapy to primary or prior recurrence 14 (70)
Proposed treatment for present recurrence: n (%)
Radical surgery 4 (20)
Palliative surgery 2 (10)
Radiotherapy / Chemo-radiotherapy 5 (25)
Chemotherapy / Phase 1 5 (25)
Watch and wait or palliative care 4 (20)
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Factors restricting treatment
Even without safety checking, treatment volume was <100% of 
PTVs in 16/20 patients; the proportion of the PTV beyond reach 
was 17±25%. In patients assumed to have preparation before 
treatment, the proportion of PTV that could not be targeted due 
to (i) bone ranged from 0–66%, (ii) major nerves ranged from 
0–51%, and (iii) bladder or bowel ranged from 0–14%. Without 
preparation, up to 75% of PTVs were not targetable due to risk 
to bowel, and up to 15% due to risk to bladder. Other restrictions 
on targeting that could not be mitigated by preparation strategies 
were (i) close proximity of the femoral artery (3% of PTV for 
an inguinal lesion), and (ii) the liver and kidney too close to the 
superior and inferior tumour margins (15% of PTV in Morri-
son’s pouch).
Comparing T2W imaging and DWI for defining GTV 
and PTV
Tumours were restricted in diffusion relative to surrounding 
normal tissues in 13/20 patients, which increased their conspi-
cuity on DWI compared to T2W imaging. DWI-GTV (58.8 ± 
87.0 ml, range: 1.0–338.4 ml) was smaller than GTV measured on 
T2W imaging (difference: 16.9±23.0%, p = 0.005). T2-PTVs (82.6 
± 103.2 ml, range: 1.1–355.4 ml) were not significantly different 
to DWI-PTVs (85.6 ± 118.0 ml, range: 1.6–404.6 ml, p = 0.92), 
or to the PTV defined with reference to all available imaging (p = 
0.60). However, discrepancies between T2-PTV and DWI-PTV 
locations were noted (Figure  4). These were worst for the LR 
co-ordinate (phase-encode imaging direction) (maximum/mean 
± SD: 10.3/3.8 ± 2.8 mm). Discrepancy of the FH co-ordinate 
(slice-encode direction) was 7.3/3.1 ± 2.2 mm, and of the AP 
co-ordinate (frequency-encode direction) was 5.3/1.5 ± 1.2 mm.
DISCuSSIon
These preliminary data indicate that ≥50% of recurrent gynae-
cological tumour volumes were targetable in 30% of patients 
without preparation strategies, or in 55% of patients when strat-
egies for bladder and/or bowel emptying and filling, as used for 
fibroid treatments were assumed to ensure treatment safety.18 We 
did not actually implement these preparations strategies, but they 
are already used to promote safety during some radiotherapy 
regimes to prostate and gynaecological tumours by reducing 
movement and inter fraction inconsistencies.19
The main restrictions for targeting lesions were disease beyond 
focal range of the transducer, and bone in the beam path (sacrum/
coccyx medially and/or superiorly, and iliac bones laterally and/
or superiorly). In five patients, bone was a barrier because some 
of the lesion was too close to a bone surface; in 10, bone could 
have been avoided by beam angulation, but this placed disease 
beyond reach of the transducer. The Sonalleve transducer has a 
focal length of 14 cm, which allows targeting of lesions up to 10 
cm below the skin with a vertical beam, or less with an angled 
beam. To minimize the requirement for beam angulation and 
maximise the acoustic window through the sciatic notch, most 
patients were in the supine-oblique position. Ideal angulation 
was limited by the constraints of the MR scanner bore in some 
cases, a factor reported by others in a rectal cancer feasibility 
study.20 It would be feasible to treat more patients if a longer focal 
length transducer were available that did not have a beam profile 
too wide to be limited by neighbouring bone.
In keeping with recognised patterns of recurrence, the most 
common target lesion site was the vaginal vault. The three 
Figure 3.(a) A 64-year-old endometrial cancer patient with a lower vaginal recurrence, who was classified as feasible to treat 
(GTV = 20.6 ml, PTV = 25.6 ml, TVoptimal = 18.4 ml, or 72% of PTV). Treatment was planned using 22 × 8 mm diameter cells, with an 
estimated treatment time of 50 min. (b) A 65-year-old ovarian cancer patient with a large tumour (GTV = 249 ml, PTV = 359 ml, 
TVoptimal = 122 ml, or 34% PTV). Treatment was not feasible despite using three different approaches (left supine oblique approach 
only shown).
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non-accessible vaginal vault lesions were in females with a high 
body mass index. Recurrent lesions located low in the pelvis, or 
superficially in inguinal or peritoneal regions, were more acces-
sible. The most challenging locations to target were those higher 
up the pelvic sidewall, where the bony pelvis obstructed acoustic 
access, and the proximity of major nerve roots also presented a 
risk. Lesions located above the level of the sciatic notch in the 
posterior pelvis are unlikely to be suitable for HIFU treatment 
using an extra corporeal technique.
As expected, smaller lesions would be more feasible to treat than 
larger ones. Notwithstanding obstruction by bone, and partial 
volumes beyond the focal range of the transducer, the potentially 
large number of sonications, and long treatment times would 
also make safe treatments of large tumours logistically diffi-
cult. In treatments of large fibroids, treatment of just one or two 
planes within the capsule of the fibroid suffices to achieve the 
desired >80% non-perfused volume necessary for symptomatic 
relief.10 The same may apply in these malignant lesions where 
targeting the well-oxygenated periphery may achieve the desired 
symptomatic relief.
GTVs in this study were defined as for EBRT, representing 
macroscopic tumour. As with our data, downsizing of the GTV 
on DWI has been reported in studies prior to EBRT in rectal and 
anal tumours.21,22 DWI may also increase delineation confidence 
for inexperienced readers, with greater inter observer agree-
ment.21 The PTVs in this study differed from those used in plan-
ning EBRT, as they included the GTV, but not structures with 
clinically suspicious involvement (the clinical target volume), or 
additional margins to account for set-up errors. Our PTVs were 
always larger than GTVs, but the degree of difference was incon-
sistent between patients because it was determined by the eccen-
tricity of the GTV. Difference in definition of PTVs for treatment 
planning of MRgHIFU and EBRT are crucially important to 
understand during multi disciplinary discussions.
The sequence-dependent differences in GTV in this study did 
not affect PTV size, but resulted in PTV displacements. These 
displacements would have resulted in inaccurate cell placement 
if PTV definition were based on DWI alone. A spatial discrep-
ancy of ±4 mm equates to 2 incorrectly positioned 4 mm diam-
eter treatment cells in every line of that imaging plane (one 
under treated, one over treated). Our measurements show that 
this clinically relevant degree of error occurred in the phase-en-
code direction in approximately half of the patients using DWI. 
Other studies that have looked at the accuracy of DWI for radio-
therapy treatment planning have shown similar results,22,23 indi-
cating that DWI assists tumour outlining, but that T2W imaging 
is needed for planning accuracy.
A limitation of the PTV analyses was that a single observer 
defined all PTVs, and that only their volumes and central loca-
tions were considered. Available software did not allow compar-
ison of PTV shapes, which could be done using radiotherapy 
treatment planning software.22 However, a fundamental differ-
ence is the need to adjust MRgHIFU treatments in real time 
(to take into account heating patterns seen intra procedurally), 
rather than following a pre-determined treatment plan. Treat-
ment volumes were measured as the sum of individual treatment 
Figure 4.Displacement of DWI-PTVs relative to T2-PTVs. Displacements were worse in the phase-encode (LR) direction, and in the 
slice-select (FH) direction, than in the frequency-encode (AP) direction.
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cell volumes, and did not consider any overlap between them. 
However, we mitigated this potential over estimate of treatment 
volume by using the PTV for the ±50% comparison. Comparison 
with the smaller GTV would have resulted in one more patient 
being classified as treatable if optimally prepared, and two more 
as treatable without preparation. Clinically, the spacing of neigh-
bouring cells would be adjusted to take account of thermal dose 
dimensions, but this real-time variation could not be assessed 
here.
This virtual planning study also could not establish the acoustic 
exposure conditions necessary to achieve ablation. These may 
be affected by tumour vascularity, but administration of Gado-
linium contrast agent to help in estimating this was not justified 
here. Attenuation or aberration of the ultrasound beam by fat 
may be another factor in effective dose delivery.24,25 It remains 
to be established whether sufficient energy can be focused at the 
required depth through fat layers in the pelvis, without excessive 
risk to surrounding OARs.
ConCluSIon
We have showed the potential accessibility of different sites of 
recurrent gynaecological disease to MRgHIFU, finding that 
≥50% of tumours could be targeted in more than half of the 
patients if clinically acceptable strategies for bowel and urogen-
ital tract emptying and filling were considered. Disease beyond 
the reach of the transducer, and bone preventing an adequate 
acoustic window were limitations. The real-time adjustments 
based on heating patterns seen on intra procedural thermom-
etry, however, will fundamentally determine safety and efficacy 
of MRgHIFU in this setting, and remain to be established in a 
treatment study.
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